# Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies

> **NCT06037018** · PHASE1 · RECRUITING · sponsor: **CytoCares Inc** · enrollment: 44 (estimated)

## Conditions studied

- Non-hodgkin Lymphoma
- Acute Lymphoblastic Leukaemia
- Chronic Lymphocytic Leukemia

## Interventions

- **BIOLOGICAL:** CC312

## Key facts

- **NCT ID:** NCT06037018
- **Lead sponsor:** CytoCares Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-07
- **Primary completion:** 2026-03
- **Final completion:** 2026-03
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2025-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06037018

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06037018, "Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06037018. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*